Published in J Cell Biochem on February 15, 2004
Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep (2005) 1.36
Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants. J Cell Biol (2004) 1.29
aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A (2009) 1.15
Unraveling the molecular targets pertinent to junction restructuring events during spermatogenesis using the Adjudin-induced germ cell depletion model. J Endocrinol (2007) 0.93
Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy. BMC Nephrol (2012) 0.87
Ubiquitous SPRY domains and their role in the skeletal type ryanodine receptor. Eur Biophys J (2009) 0.84
Dynamics of the SPRY domain-containing SOCS box protein 2: flexibility of key functional loops. Protein Sci (2006) 0.83
PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets (2010) 0.83
Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. Cell Death Dis (2014) 0.78
Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells. Int J Oncol (2013) 0.78
Plant-derived SAC domain of PAR-4 (Prostate Apoptosis Response 4) exhibits growth inhibitory effects in prostate cancer cells. Front Plant Sci (2015) 0.76
Expression Pattern of the Pro-apoptotic Gene PAR-4 During the Morphogenesis of MCF-10A Human Mammary Epithelial Cells. Cancer Microenviron (2010) 0.76
A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4. Clin Exp Metastasis (2016) 0.76
Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity. Int J Mol Med (2017) 0.75
The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell (2009) 2.80
Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol (2004) 2.01
Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell (2005) 1.82
Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol (2003) 1.49
Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol (2005) 1.38
Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res (2003) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res (2007) 1.28
Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res (2007) 1.25
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem (2005) 1.18
Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res (2007) 1.14
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol (2007) 1.14
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res (2008) 1.13
Mechanisms of apoptosis by the tumor suppressor Par-4. J Cell Physiol (2012) 1.13
RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res (2009) 1.08
Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol (2011) 1.07
The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res (2006) 1.06
Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Res (2012) 1.06
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther (2007) 1.03
Regulation of cancer cell survival by Par-4. Ann N Y Acad Sci (2005) 1.03
Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Res (2008) 1.00
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther (2008) 1.00
Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol Ther (2011) 0.99
Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther (2008) 0.95
In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res (2002) 0.91
Endocrine expression of the active form of TGF-beta1 in the TGF-beta1 null mice fails to ameliorate lethal phenotype. Cytokine (2002) 0.89
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem (2003) 0.87
Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol Ther (2010) 0.87
Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer (2012) 0.87
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol (2014) 0.79
Par(-4)oxysm in breast cancer. Cancer Cell (2013) 0.79
Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biol Ther (2005) 0.78
Molecular therapy intervention prospects in prostate cancer. Curr Pharm Des (2004) 0.78
Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells. Int J Oncol (2013) 0.78
ErbB4 targeting approaches for prostate cancer treatment. Cancer Biol Ther (2008) 0.76
Par-4 for molecular therapy of prostate cancer. Curr Drug Targets (2003) 0.76
Regulation of Par-4 by oncogenic Ras. Methods Enzymol (2006) 0.76
"D" approach to prevent metastasis. Cancer Biol Ther (2007) 0.75
Par-4 prevents breast cancer recurrence. Breast Cancer Res (2013) 0.75
Cancer-selective apoptosis by tumor suppressor par-4. Adv Exp Med Biol (2014) 0.75